Search results
Jan 14, 2022 · The evidence generated by pivotal RCTs supports the use of triple therapy in patients who present for the first time and have severe airway obstruction, are symptomatic, have had frequent moderate or severe exacerbations in the previous year, and have peripheral eosinophilia.
- Dual Bronchodilator in the Era of Triple Therapy - PMC
Finally, in order to optimize pharmacotherapy in stable...
- Beyond Dual Bronchodilation - Triple Therapy, When and Why
The evidence generated by pivotal RCTs supports the use of...
- Dual Bronchodilator in the Era of Triple Therapy - PMC
Oct 28, 2020 · Finally, in order to optimize pharmacotherapy in stable COPD, we propose an algorithm on performing step-up of therapy from dual bronchodilation to triple therapy and step down from triple to double bronchodilation taking into account the extremely heterogeneous population of COPD patients.
- Andriana I Papaioannou, Stelios Loukides, Petros Bakakos, Epameinondas N Kosmas, Nikoletta Rovina, P...
- 10.2147/COPD.S273987
- 2020
- 2020
Jan 14, 2022 · The evidence generated by pivotal RCTs supports the use of triple therapy in patients who present for the first time and have severe airway obstruction, are symptomatic, have had frequent moderate or severe exacerbations in the previous year, and have peripheral eosinophilia.
Nov 7, 2023 · Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-acting β 2 -agonists (LABAs) in combination is currently the mainstay of treatment for chronic obstructive pulmonary disease (COPD).
Nov 6, 2018 · The Global Initiative for Obstructive Lung Disease (GOLD) management strategy recommend triple therapy with inhaled corticosteroids, LABA, and LAMA for GOLD group D patients who develop further exacerbations after receiving initial dual treatment of LABA and LAMA. 3 4 Triple therapy using multiple inhalers has been shown to improve forced expira...
- Yayuan Zheng, Jianhong Zhu, Yuyu Liu, Weiguang Lai, Chunyu Lin, Kaifen Qiu, Junyan Wu, Weimin Yao
- 2018
Oct 28, 2020 · IMPACT trial reached its primary outcome in favor of fixed triple (FVU) therapy since the rate of moderate or severe exacerbations was significantly lower with FVU compared to Fluticasone furoate/Vilanterol or Umeclidinium/Vilanterol. FEV 1 and SGRQ total score significantly differed in favor of fixed triple therapy.
a small but significant reduction of the exacerbation rate with the addition of an inhaled corticosteroid to dual long acting bronchodilation in patients with chronic obstructive pulmonary disease and severe or very severe airway obstruction with at least one exacerbation in the previous year.
